Phase I Study of Patupilone and RAD001
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00496600 |
Recruitment Status :
Completed
First Posted : July 4, 2007
Last Update Posted : June 14, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Refractory Malignancy | Drug: Patupilone Drug: RAD001 | Phase 1 |
Primary Endpoint To identify the maximum tolerated doses (MTD) of the combination of patupilone and RAD001
Secondary Endpoints To assess the toxicity of patupilone and RAD001 To determine if concentrations of RAD001 are elevated in the presence of patupilone To evaluate tumor response using standard imaging modalities (CT scan, x-ray, bone scan) To develop pharmacodynamic markers that may predict or indicate response to mTOR inhibition or patupilone treatment.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 42 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Study of Patupilone and RAD001 in Patients With Refractory Solid Tumor Malignancy |
Study Start Date : | July 2007 |
Actual Primary Completion Date : | February 2011 |
Actual Study Completion Date : | February 2011 |
- Drug: Patupilone
RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
- Drug: RAD001
RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
- To identify the maximum tolerated doses (MTD) of the combination of patupilone and RAD001 [ Time Frame: 3 years ]
- find toxicity of patupilone and RAD001, see if concentrations of RAD001 are elevated with patupilone, evaluate tumor response using standard imaging, develop pharmacodynamic markers that may predict/indicate response to mTOR inhibition or patupilone trt [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients must have malignancy refractory to standard therapy or for whom no standard, effective therapy is available.
- Patient must have performance status 0-2 on the ECOG Performance Status (see Appendix B)
- Patient's disease must be measurable (RECIST) or evaluable (e.g., cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill RECIST criteria for measurable disease).
- Patients must have intact intestinal absorption
- Patients must have adequate organ function
- Patient must have recovered from toxicity of prior chemotherapy and/or radiotherapy. Patient may not have received chemotherapy in the prior 4 weeks. Patients may have not received radiotherapy in the prior 3 weeks.
- Patient (male or female) must be ≥ 18 years old.
- Women must not be pregnant or lactating. Female patients of childbearing potential must have a negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study, and for three months following discontinuation of study drug.
- Signed written informed consent.
Exclusion Criteria:
- Patient has received greater than 3 prior cytotoxic regimens for metastatic disease.
- Prior therapy with epothilones, rapamycin, rapamycin analogs, or known sensitivity to these agents
- Prior treatment with any investigational drug within the preceding 4 weeks.
- Patient has history of bone marrow or stem cell transplant.
- Patient has received prior radiation therapy to greater than 25% of the bone marrow.
- Patients has newly diagnosed, not yet treated or uncontrolled brain metastases or leptomeningeal disease.
- Patient has known hypersensitivity to the components of study drugs or its analogs.
- Patient with known Grade 3 or 4 hypersensitivity to macrolide antibiotics (eg. clarithromycin, erythromycin, azithromycin).
- Patient with any active (acute or chronic) or uncontrolled infection requiring systemic therapy.
- Patients with chronic treatment with systemic steroids or another immunosuppressive agent
- Patient with known HIV infection.
- Patients with unresolved diarrhea within the last 7 days prior to start of treatment.
- Concomitant treatment with medications that are listed as clinically relevant inducers or inhibitors of cytochrome P450 (CYP3A).
- Patients taking Coumadin® or other agents containing warfarin, with the exception of low dose Coumadin® (1 mg or less) administered prophylactically for maintenance of in-dwelling lines or ports
- Herbal preparations or related over-the-counter preparations containing herbal ingredients (eg. St. John's Wort)
- Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia, or severely impaired lung function
- Any patient with uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
- Any patient with nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy
- Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
- Patients receiving immunization with attenuated live vaccines during study participation.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00496600
United States, New Jersey | |
The Cancer Institute of New Jersey | |
New Brunswick, New Jersey, United States, 08901 |
Principal Investigator: | Mark Stein, MD | Rutgers, The State University of New Jersey |
Responsible Party: | University of Medicine and Dentistry of New Jersey |
ClinicalTrials.gov Identifier: | NCT00496600 |
Other Study ID Numbers: |
050612 CRAD001US16 0220060307 ( Other Identifier: CINJ IRB ) |
First Posted: | July 4, 2007 Key Record Dates |
Last Update Posted: | June 14, 2012 |
Last Verified: | June 2012 |
Neoplasms Everolimus Epothilone B Antineoplastic Agents Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |